Drug Profile
Influenza A virus H9N2 vaccine - National Resilience
Alternative Names: H9N2 vaccine - National Resilience; Reverse genetic reassortant H9N2 influenza vaccineLatest Information Update: 15 Feb 2022
Price :
$50
*
At a glance
- Originator
- Developer National Resilience
- Class Influenza A vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Influenza A virus H9N2 subtype
Most Recent Events
- 15 Feb 2022 Discontinued - Phase-II for Influenza A virus H9N2 subtype in USA (IM) (National Resilience website, February 2022)
- 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
- 25 Oct 2016 Phase-II clinical trials in Influenza-A virus H9N2 subtype in USA (IM)